Skip to main content

Advertisement

Log in

The Burden of Diabetes and Hyperlipidemia in Treated HIV Infection and Approaches for Cardiometabolic Care

  • Metabolic Complications and Comorbidity (JM Kilby, Section Editor)
  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Treatment of HIV infection with highly active antiretroviral therapy (HAART) confers survival and quality of life benefits. However, these significant benefits are at the cost of metabolic complications with associated increased risk of type 2 diabetes and cardiovascular disease. These chronic diseases add complexity to the standards of care in HIV infection and much remains unknown about the natural histories of diabetes and hyperlipidemia in this setting. This review examines recent research findings in diabetes and hyperlipidemia in HIV infection, juxtaposed on our prior understanding of these diseases. It also reviews the current evidence base and clinical guidelines for diabetes and lipid management and cardiometabolic prevention in HIV-infected HAART recipients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. United Nations. UNAIDS Report on the global AIDS epidemic. 2010.

  2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35:S64–71.

    Article  Google Scholar 

  3. Diabetes Atlas fecNUc-c, David Whiting (co-chair), Leonor Guariguata, Anselm Hennis, Abdullatif Husseini, Linong Ji, Katarzyna Kissimova-Skarbek, Ingrid Libman, Elizabeth Mayer-Davis, Ayesha Motala, Venkat Narayan, Ambady Ramachandran, Gojka Roglic, Jonathan Shaw, Nick Wareham, Ping Zhang. IDF Diabetes Atlas (5th Edition). 2011.

  4. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, Grunfeld C, Raghavan SS. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6:114–21.

    Article  PubMed  CAS  Google Scholar 

  5. Kilby JM, Tabereaux P. Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:46–50.

    Article  PubMed  CAS  Google Scholar 

  6. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med. 1997;127:947.

    PubMed  CAS  Google Scholar 

  7. Eastone JA, Decker C. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med. 1997;127:948.

    PubMed  CAS  Google Scholar 

  8. Dubé MP, Johnson D, Currier JS, Leedom JM. Protease-inhibitor-associated hyperglycaemia. Lancet. 1997;350:713–4.

    Article  PubMed  Google Scholar 

  9. Carr A, Samaras K, Burton S, Freund J, Chisholm D, Cooper D. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors. AIDS. 1998;12:F51–8.

    Article  PubMed  CAS  Google Scholar 

  10. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm D, Cooper D. Natural history, diagnosis and prediction of HIV protease inhibitor-induced lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet. 1999;353:2094–9.

    Google Scholar 

  11. Hadigan C, Meigs J, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D’Agostino RB, Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130–9.

    Article  PubMed  CAS  Google Scholar 

  12. Calza L, Masetti G, Piergentili B, et al. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection. Int J STD AIDS. 2011;22:43–5.

    Article  PubMed  CAS  Google Scholar 

  13. Brown T, Cole S, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2000;165:1179–84.

    Article  Google Scholar 

  14. De Wit S, Sabin C, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte A, Fontas E, Law MG, Friis-Møller N, Phillips A, Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Incidence and risk factors for new-onset diabetes in HIV-infected patients: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31:1224–9.

    Article  PubMed  Google Scholar 

  15. •• Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R; Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011;53:1130–9. This important paper reports the associations of diseases of aging in treated HIV in a long established and large cohort. The incidence of CVD, diabetes, osteoporosis, and other diseases associated with aging are reported, and related to drug exposures.

    Article  PubMed  Google Scholar 

  16. •• Capeau J, Bouteloup V, Katlama C, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012;26:303–14. While a smaller cohort than other observational studies, this study examined diabetes incidence in relation to traditional and HIV-specific risk factors.

    Article  PubMed  CAS  Google Scholar 

  17. Polsky S, Floris-Moore M, Schoenbaum EE, Klein RS, Arnsten JH, Howard AA. Incident hyperglycaemia among older adults with or at-risk for HIV infection. Antivir Ther. 2011;16:181–8.

    Article  PubMed  Google Scholar 

  18. Howard AA, Floris-Moore M, Arnsten JH, Santoro N, Fleischer N, Lo Y, Schoenbaum EE. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis. 2005;40:1492–9.

    Article  PubMed  CAS  Google Scholar 

  19. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, Weber K, Piessens E, Robison E, Anastos K. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298–302.

    Article  PubMed  CAS  Google Scholar 

  20. Tien PC, Schneider M, Cole SR, Levine AM, Cohen M, DeHovitz J, Young M, Justman JE. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women’s Interagency HIV Study. AIDS. 2007;21:1739–45.

    Article  PubMed  CAS  Google Scholar 

  21. Yoon C, Gulick R, Hoover DR, Vaamonde CM, Glesby MJ. Case–control study of diabetes mellitus in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;37:1464–9.

    Article  PubMed  Google Scholar 

  22. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care. 2007;30:113–9.

    Article  PubMed  CAS  Google Scholar 

  23. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S, INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007;21:2445–53.

    Article  PubMed  CAS  Google Scholar 

  24. Milner KL, Van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, Dore GJ, Zekry A, Weltman M, Fragomeli V, George J, Chisholm DJ. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology. 2010;138:932–41.

    Article  PubMed  Google Scholar 

  25. Mehta SH, Moore R, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr. 2003;33:577–84.

    Article  PubMed  CAS  Google Scholar 

  26. Lee GA, Rao M, Mulligan K, et al. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS. 2007;21(16):2183–90.

    Article  PubMed  CAS  Google Scholar 

  27. Lee GA, Lo JC, Aweeka F, et al. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis. 2006;43(5):658–60.

    Article  PubMed  CAS  Google Scholar 

  28. Taylor SA, Lee GA, Pao VY, et al. Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr. 2010;55(3):361–4.

    Article  PubMed  CAS  Google Scholar 

  29. Pao VY, Lee GA, Taylor S, et al. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers. AIDS. 2010;24(2):265–70.

    Article  PubMed  CAS  Google Scholar 

  30. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case control study. Lancet. 2003;361:726–35.

    Article  Google Scholar 

  31. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309–16.

    Article  PubMed  CAS  Google Scholar 

  32. van der Valk M, Gisolf E, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA. Prometheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847–55.

    Article  PubMed  Google Scholar 

  33. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J American Med Assoc. 2004;292:191–201.

    Article  CAS  Google Scholar 

  34. Falutz J. Management of fat accumulation in patients with HIV infection. Curr HIV/AIDS Rep. 2011;8:200–8.

    Article  PubMed  Google Scholar 

  35. Martínez E. Disorders of fat partitioning in treated HIV-infection. Best Pract Res Clin Endocrinol Metab. 2011;25:415–27.

    Article  PubMed  Google Scholar 

  36. Paik IJ, Kotler D. The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab. 2011;25:469–78.

    Article  PubMed  Google Scholar 

  37. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;50:499–505.

    Article  PubMed  Google Scholar 

  38. Levitt NS, Bradshaw D. The impact of HIV/AIDS on Type 2 diabetes prevalence and diabetes healthcare needs in South Africa: projections for 2010. Diabet Med. 2006;23:103–4.

    Article  PubMed  CAS  Google Scholar 

  39. Julius H, Basu D, Ricci E, Wing J, Basu JK, Pocaterra D, Bonfanti P. The burden of metabolic diseases amongst HIV positive patients on HAART attending The Johannesburg Hospital. Curr HIV Res. 2011;9:247–52.

    PubMed  CAS  Google Scholar 

  40. Hall V, Thomsen R, Henriksen O, Lohse N. Diabetes in Sub Saharan Africa 1999–2011: epidemiology and public health implications. A systematic review. BMC Publ Health. 2011;11:564.

    Article  Google Scholar 

  41. Gupta S, Shenoy V, Bairy I, Srinivasa H, Mukhopadhyay C. Diabetes mellitus and HIV as co-morbidities in tuberculosis patients of rural south India. J Infect Public Health. 2011;4:140–4.

    Article  PubMed  Google Scholar 

  42. Dubé MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab. 2011;25:429–42.

    Article  PubMed  Google Scholar 

  43. Kotler DP, Ionescu G, Johnson JA, Inada Y, He Q, Engelson ES. Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clin Infect Dis. 2003;37 Suppl 2:S47–51.

    Article  PubMed  CAS  Google Scholar 

  44. Samaras K, Gan S, Peake PW, Carr A, Campbell LV. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obesity. 2009;17:53–9.

    Article  PubMed  CAS  Google Scholar 

  45. Kim PS, Woods C, Dutcher L, Georgoff P, Rosenberg A, Mican JA, Kopp JB, Smith MA, Hadigan C. Increased prevalence of albuminuria in HIV-infected adults with diabetes. PLoS One 2011;Sep 13 (Epub).

  46. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk Factors for ESRD in HIV-Infected Individuals: Traditional and HIV-Related Factors. Am J Kidney Dis 2011;Dec 27 (Epub).

  47. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant. 2011;26:3923–9.

    Article  PubMed  CAS  Google Scholar 

  48. Glover SJ, Burgess P, Cohen DB, Harding SP, Hofland HW, Zijlstra EE, Allain TJ. Prevalence of diabetic retinopathy, cataract and visual impairment in patients with diabetes in sub-Saharan Africa. Br J Ophthalmol. 2012;96:156–61.

    Article  PubMed  Google Scholar 

  49. • Reijmer YD, van den Berg E, de Bresser J, Kessels RP, Kappelle LJ, Algra A, Biessels GJ; Utrecht Diabetic Encephalopathy Study Group. Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors. Diabetes Metab Res Rev 2011;27:195–202. An important study that documents treatment biases for people living with HIV, indicating suboptimal treatment of traditional cardiovascular risk factors that would be considered the standard of care.

    Article  PubMed  Google Scholar 

  50. • McCutchan JA, Marquie-Beck JA, Fitzsimons CA, Letendre SL, Ellis RJ, Heaton RK, Wolfson T, Rosario D, Alexander TJ, Marra C, Ances BM, Grant I; CHARTER Group. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 2012;78:485–92. A further study that documents less frequent achievement of the appropriate standards of care in HIV infection with diabetes.

    Article  PubMed  CAS  Google Scholar 

  51. Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Møller N. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation. 2009;119:805–11.

    Article  PubMed  Google Scholar 

  52. Association AD. Standards of Medical Care in Diabetes—2012. Diabetes Care. 2012;35:S11–63.

    Article  Google Scholar 

  53. Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Mostardt S, Neumann A, Brockmeyer NH, Gelbrich G, Erbel R, Neumann T, On behalf of the German Competence Network Heart Failure and the German Competence Network for HIV/AIDS. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiolog. 2012;19:267–74.

    Article  Google Scholar 

  54. Backus LI, Boothroyd D, Philips B, Belperio P, Halloran J, Mole L. Assessment of the quality of diabetes care for HIV-infected patients in a national health care system. AIDS Patient Care STDS. 2011;25:203–6.

    Article  PubMed  Google Scholar 

  55. Satlin MJ, Hoover D, Glesby MJ. Glycemic control in HIV-infected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines. AIDS Patient Care STDS. 2011;25:5–12.

    Article  PubMed  Google Scholar 

  56. Kalra S, Unnikrishnan A, Raza SA, Bantwal G, Baruah MP, Latt TS, Shrestha D, John M, Katulanda P, Somasundaram N, Sahay R, Pathan F. South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. Indian J Endocrinol Metab. 2011;14:242–50.

    Article  Google Scholar 

  57. Petoumenos K, Worm S. HIV infection, aging and cardiovascular disease: epidemiology and prevention. Sex Health. 2011;8:465–73.

    Article  PubMed  Google Scholar 

  58. Janiszewski PM, Ross R, Despres JP, Lemieux I, Orlando G, Carli F, Bagni P, Menozzi M, Zona S, Guaraldi G. Hypertriglyceridemia and waist circumference predict cardiovascular risk among HIV patients: a cross-sectional study. PLoS One 2011;6:Sept 22 (Epub).

  59. Bucher H, Richter W, Glass T, et al. Small dense lipoproteins, apolipoprotein B and risk of coronary events in HIV-infected patients on antiretroviral therapy: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2011;Dec 9 (Epub).

  60. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC, Swiss HIV, Cohort Study. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006;7:404–10.

    Article  PubMed  CAS  Google Scholar 

  61. Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D’Arminio Monforte A, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD, D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006;7:218–30.

    Article  PubMed  CAS  Google Scholar 

  62. •• The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993–2003. An important paper documenting health benefits in cardiovascular event reduction after smoking cessation in HIV-infected participants.

    Article  Google Scholar 

  63. •• The DAD Study Group. Class of antiretrovirals and risk of myocardial infarction. N Engl J Med 2007;356:1723–35. Another analysis from the D:A:D Study Group dissecting medication exposures and risk of incident cardiac disease.

    Article  Google Scholar 

  64. Triant VA, Josephson F, Rochester CG, Althoff KN, Marcus K, Munk R, Cooper C, D’Agostino RB, Costagliola D, Sabin CA, Williams PL, Hughes S, Post WS, Chandra-Strobos N, Guaraldi G, Young SS, Obenchain R, Bedimo R, Miller V, Strobos J. Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. Clin Infect Dis. 2012;54:408–13.

    Article  PubMed  CAS  Google Scholar 

  65. •• Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471–7. The first study showing that dietary intervention at initiation of HAART can prevent development of lipid disturbances.

    Article  PubMed  CAS  Google Scholar 

  66. Petoumenos K, Worm S, Reiss P, de Wit S, d’Arminio Monforte A, Sabin C, Friis-Møller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M, D:A:D Study Group. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med. 2011;12:412–21.

    Article  PubMed  CAS  Google Scholar 

  67. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318–30.

    Article  PubMed  CAS  Google Scholar 

  68. Ribaudo H, Benson C, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011;52:929–40.

    Article  PubMed  CAS  Google Scholar 

  69. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25:1993–2004.

    Article  PubMed  CAS  Google Scholar 

  70. Worm SW, Kamara D, Reiss P, Kirk O, El-Sadr W, Fux C, Fontas E, Phillips A, D’Arminio Monforte A, De Wit S, Petoumenos K, Friis-Mller N, Mercie P, Lundgren JD, Sabin C. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011;25:1497–504.

    Article  PubMed  CAS  Google Scholar 

  71. Lazzaretti RK, Kuhmmer R, Sprinz E, Polanczyk CA, Ribeiro JP. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial. J Am Coll Cardiol. 2012;59:979–88.

    Article  PubMed  CAS  Google Scholar 

  72. Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG, DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17:491–501.

    Article  PubMed  Google Scholar 

  73. Curtis J, Newall HD, Samaras K. The heart of the matter: Cardiometabolic care in youth with psychosis. Early Interven Psychosis 2012.

Download references

Disclosure

Conflicts of interest: K. Samaras: has been a consultant for MSD (sitaglitpin expert advisory committee); receives royalties from for Fast Facts Diabetes, Oxford Health Press; has received payment for development of educational presentations including service on speakers’ bureaus as a speaker on obesity management; and has received travel/accommodations expenses covered or reimbursed from MSD (attendance at EASD, Lisbon, 20122).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katherine Samaras.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Samaras, K. The Burden of Diabetes and Hyperlipidemia in Treated HIV Infection and Approaches for Cardiometabolic Care. Curr HIV/AIDS Rep 9, 206–217 (2012). https://doi.org/10.1007/s11904-012-0124-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-012-0124-x

Keywords

Navigation